+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Vasculitis Treatment: Global Strategic Business Report

  • PDF Icon

    Report

  • 183 Pages
  • March 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5309834

Global Vasculitis Treatment Market to Reach $662.4 Million by 2030

The global market for Vasculitis Treatment estimated at US$465.2 Million in the year 2022, is projected to reach a revised size of US$662.4 Million by 2030, growing at a CAGR of 4.5% over the analysis period 2022-2030. Biologics, one of the segments analyzed in the report, is projected to record 5.4% CAGR and reach US$360.6 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Corticosteroids segment is readjusted to a revised 3.2% CAGR for the next 8-year period.

The U.S. Market is Estimated at $137.6 Million, While China is Forecast to Grow at 4.1% CAGR

The Vasculitis Treatment market in the U.S. is estimated at US$137.6 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$115.2 Million by the year 2030 trailing a CAGR of 4.1% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.1% and 3.7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

Select Competitors (Total 23 Featured) -

  • AB Science SA
  • Ablynx NV
  • Acorda Therapeutics, Inc.
  • Antares Pharma, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca PLC
  • Baxter International, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Can-Fite BioPharma Ltd.
  • Celgene Corporation
  • Celltrion Healthcare Co., Ltd.
  • Coherus BioSciences
  • Daiichi Sankyo Co., Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Hospira, Inc.
  • Idera Pharmaceuticals, Inc.
  • Immunomedics, Inc.
  • Incyte Corporation
  • Lexicon Pharmaceuticals, Inc.
  • MedImmune LLC
  • Merck & Co., Inc.
  • Morphotek, Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Regeneron Pharmaceuticals, Inc.
  • Sandoz International GmbH
  • Sanofi SA
  • Takeda Pharmaceutical Co., Ltd.
  • UCB SA
  • Vertex Pharmaceuticals Inc.

What's New?

  • Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and the publisher's Research Platform
  • Complimentary updates for one year

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Vasculitis Treatment - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Vasculitis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 2: World Historic Review for Vasculitis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 3: World 16-Year Perspective for Vasculitis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
  • Table 4: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 5: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 6: World 16-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Immunosuppressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 8: World Historic Review for Immunosuppressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 9: World 16-Year Perspective for Immunosuppressants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 10: World Recent Past, Current & Future Analysis for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 11: World Historic Review for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 12: World 16-Year Perspective for Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 13: World Vasculitis Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
III. MARKET ANALYSIS
  • UNITED STATES
  • Vasculitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
  • Table 14: USA Recent Past, Current & Future Analysis for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 15: USA Historic Review for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 16: USA 16-Year Perspective for Vasculitis Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants and Biologics for the Years 2014, 2023 & 2030
  • CANADA
  • Table 17: Canada Recent Past, Current & Future Analysis for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 18: Canada Historic Review for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 19: Canada 16-Year Perspective for Vasculitis Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants and Biologics for the Years 2014, 2023 & 2030
  • JAPAN
  • Vasculitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
  • Table 20: Japan Recent Past, Current & Future Analysis for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 21: Japan Historic Review for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 22: Japan 16-Year Perspective for Vasculitis Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants and Biologics for the Years 2014, 2023 & 2030
  • CHINA
  • Vasculitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
  • Table 23: China Recent Past, Current & Future Analysis for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 24: China Historic Review for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 25: China 16-Year Perspective for Vasculitis Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants and Biologics for the Years 2014, 2023 & 2030
  • EUROPE
  • Vasculitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
  • Table 26: Europe Recent Past, Current & Future Analysis for Vasculitis Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 27: Europe Historic Review for Vasculitis Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 28: Europe 16-Year Perspective for Vasculitis Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
  • Table 29: Europe Recent Past, Current & Future Analysis for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 30: Europe Historic Review for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 31: Europe 16-Year Perspective for Vasculitis Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants and Biologics for the Years 2014, 2023 & 2030
  • FRANCE
  • Vasculitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
  • Table 32: France Recent Past, Current & Future Analysis for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 33: France Historic Review for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 34: France 16-Year Perspective for Vasculitis Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants and Biologics for the Years 2014, 2023 & 2030
  • GERMANY
  • Vasculitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
  • Table 35: Germany Recent Past, Current & Future Analysis for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 36: Germany Historic Review for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 37: Germany 16-Year Perspective for Vasculitis Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants and Biologics for the Years 2014, 2023 & 2030
  • ITALY
  • Table 38: Italy Recent Past, Current & Future Analysis for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 39: Italy Historic Review for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 40: Italy 16-Year Perspective for Vasculitis Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants and Biologics for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
  • Vasculitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
  • Table 41: UK Recent Past, Current & Future Analysis for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 42: UK Historic Review for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 43: UK 16-Year Perspective for Vasculitis Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants and Biologics for the Years 2014, 2023 & 2030
  • REST OF EUROPE
  • Table 44: Rest of Europe Recent Past, Current & Future Analysis for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 45: Rest of Europe Historic Review for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 46: Rest of Europe 16-Year Perspective for Vasculitis Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants and Biologics for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
  • Vasculitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • Table 47: Asia-Pacific Recent Past, Current & Future Analysis for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 48: Asia-Pacific Historic Review for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 49: Asia-Pacific 16-Year Perspective for Vasculitis Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants and Biologics for the Years 2014, 2023 & 2030
  • REST OF WORLD
  • Table 50: Rest of World Recent Past, Current & Future Analysis for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 51: Rest of World Historic Review for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 52: Rest of World 16-Year Perspective for Vasculitis Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants and Biologics for the Years 2014, 2023 & 2030
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AB Science SA
  • Ablynx NV
  • Acorda Therapeutics, Inc.
  • Antares Pharma, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca PLC
  • Baxter International, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Can-Fite BioPharma Ltd.
  • Celgene Corporation
  • Celltrion Healthcare Co., Ltd.
  • Coherus BioSciences
  • Daiichi Sankyo Co., Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Hospira, Inc.
  • Idera Pharmaceuticals, Inc.
  • Immunomedics, Inc.
  • Incyte Corporation
  • Lexicon Pharmaceuticals, Inc.
  • MedImmune LLC
  • Merck & Co., Inc.
  • Morphotek, Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Regeneron Pharmaceuticals, Inc.
  • Sandoz International GmbH
  • Sanofi SA
  • Takeda Pharmaceutical Co., Ltd.
  • UCB SA
  • Vertex Pharmaceuticals Inc.

Table Information